Tirzepatide

Research-centric overview

Peptide

### Summary Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been investigated for its potential in managing type 2 diabetes and obesity. Its unique mechanism of action aims to enhance glycemic control and promote weight loss.

Community effect votes, structured logs, and side-effect summaries.

Effect profile (overview)

Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.

Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.

Research log summary heatmap

Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.

No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.

Anonymous side-effect patterns

Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.

No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.

Research footprint

Last analyzed Jun 2, 2026

Studies indexed

Human

Animal

AI analyzed

Evidence mix0% human · 0% animal · 0% cellular · 0% review

Highest phase: Preclinical onlyYears covered: 2026

Librarian pulse — latest actionsFull changelog ↓

Jun 2, 5:00 PMRe-scoredScored effects for Tirzepatide
Jun 1, 6:00 AMRefreshedRefreshed content for Tirzepatide
May 31, 6:00 AMRefreshedRefreshed content for Tirzepatide

Research & intelligence feed

Studies, clinical trials, community discussions, and news.

Behavioral Therapy With and Without GLP-1 Analogue in Patients With Morbid Obesity and Binge Eating Disorder: A Clinical Prospective Observational Study on Body Weight, Binge Eating Behavior, and Harmful Coping StrategiesClinical TrialClinicalTrials.govPublished Jul 1, 2025Added May 27, 2026

This study evaluated the effects of behavioral therapy with and without the GLP-1 analogue Tirzepatide in patients with morbid obesity and binge eating disorder. The outcomes measured included body weight, binge eating behavior, and harmful coping strategies. Not reported in abstract.

Status: RECRUITING

Clinical and Neurobehavioral Changes With GLP-1 (Glucagon-like Peptide-1) DiscontinuationClinical TrialClinicalTrials.govPublished Jun 1, 2026Added May 27, 2026

This study examines clinical and neurobehavioral changes following the discontinuation of GLP-1 receptor agonists, specifically tirzepatide. The population, dosage, and specific outcomes measured are not detailed in the abstract. The implications of these changes for patient management are not specified.

Phase: NAStatus: NOT_YET_RECRUITING

A Phase IV Placebo-controlled Single Center Trial for Tirzepatide in Idiopathic Intracranial Hypertension Trial (TIIHT)Clinical TrialClinicalTrials.govPublished Feb 1, 2026Added May 27, 2026

This study evaluated the effects of Tirzepatide in patients with Idiopathic Intracranial Hypertension (IIH) compared to a placebo. The trial was conducted at a single center, and specific outcomes related to intracranial pressure were measured. No therapeutic claims are made in the abstract.

Phase: PHASE4Status: NOT_YET_RECRUITING

Tailored Exercise Training Study Among Adults With HFpEFClinical TrialClinicalTrials.govPublished Feb 18, 2025Added May 27, 2026

Not reported in abstract.

Phase: PHASE2, PHASE3Status: RECRUITING

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal TumorsClinical TrialClinicalTrials.govPublished Feb 24, 2026Added May 27, 2026

Not reported in abstract.

Phase: PHASE1Status: RECRUITING

Conduct of the REsponses in Function and Outcomes From RYGB vs. Medication Study (REFORM) Study by Research CoordinatorsClinical TrialClinicalTrials.govPublished Aug 9, 2025Added Apr 16, 2026

Not reported in abstract.

Status: RECRUITING

A Parallel-Group Treatment, Phase 2, Double-Blind Study of Once-Weekly Subcutaneous LY3457263 Compared to Placebo in Participants With Type 2 Diabetes Mellitus on a Stable Dose of Semaglutide or Tirzepatide Who Failed to Achieve HbA1c GoalClinical TrialClinicalTrials.govPublished Mar 28, 2025Added Apr 16, 2026

This study evaluated the efficacy of once-weekly subcutaneous LY3457263 compared to placebo in participants with Type 2 Diabetes Mellitus who were on a stable dose of Semaglutide or Tirzepatide and had not achieved their HbA1c goal. The specific outcomes and numeric findings are not detailed in the abstract. The study is classified as a Phase 2 trial.

Phase: PHASE2Status: RECRUITING

A Two-Part, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of ALN-PNP With and Without a GLP1R Agonist in Adults With Homozygous PNPLA3-Related Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Clinical TrialClinicalTrials.govPublished Apr 20, 2026Added Apr 16, 2026

Not reported in abstract.

Phase: PHASE2Status: NOT_YET_RECRUITING

Semantic Scholar search for TirzepatideStudySemanticScholarAdded Dec 12, 2025

Not reported in abstract.

Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review.StudyPubMedAdded Dec 12, 2025

This narrative review highlights the importance of understanding the safety and tolerability of glucagon-like peptide-1 receptor agonists, including tirzepatide, but does not provide new data or conclusions.

External databases

Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.

Community notes

No comments yet. Share research notes, citations, or observations below.

Community research logs (detail)

No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.

Anonymous side-effect reporting (detail)

This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.

Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.

Librarian Changelog

Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.

59m agoScoring70%

Scored effects for Tirzepatide

1d agoRefreshai-researcher85%

Refreshed content for Tirzepatide

2d agoRefreshai-researcher85%

Refreshed content for Tirzepatide

3d agoRefreshai-researcher85%

Refreshed content for Tirzepatide

4d agoRefreshai-researcher85%

Refreshed content for Tirzepatide

6d agoRefreshai-researcher85%

Refreshed content for Tirzepatide

May 26Scoring70%

Scored effects for Tirzepatide

May 26task_runlibrarian-runner

Completed task: Find real articles for Tirzepatide (thin literature)

May 26Ingestiondiscovery

Searched for real articles on Tirzepatide

May 26Refreshai-researcher85%

Refreshed content for Tirzepatide

Apr 20Refreshdiscovery50%

Refreshed content for Tirzepatide

Apr 20SummaryPubMed30%

Auto-summarized study: "Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of..."

Apr 20SummarySemanticScholar0%

Auto-summarized study: "Semantic Scholar search for Tirzepatide..."

Apr 17Refreshai-researcher85%

Refreshed content for Tirzepatide

Apr 16Refreshai-researcher85%

Refreshed content for Tirzepatide

Apr 16Refreshai-researcher85%

Refreshed content for Tirzepatide